TY - JOUR
T1 - Candida antigen in the treatment of basal cell carcinoma
AU - Aftergut, Kent
AU - Curry, Mary
AU - Cohen, Jack
PY - 2005/1
Y1 - 2005/1
N2 - BACKGROUND. Basal cell carcinoma (BCC) is the most common skin cancer. Recently, there has been renewed interest in various immunotherapies in the treatment of BCC. The current study is a randomized, open-label, placebo-controlled trial of intralesional Candida antigen in the treatment of nodular BCC. OBJECTIVE. The objective of this study was to evaluate the safety and efficacy of intralesional Candida antigen in the treatment of BCC. RESULTS. In the control group, no patients had complete clearing of their tumor. In the Candida group, 10 of 17 (56%) patients had complete clearing of their tumor. The Fisher exact test was used to compare the two treatment groups. This showed the difference in clearance rates to be of borderline significance, with a p value of .105. CONCLUSION. Although immunotherapy with repeated injections of Candida antigen appears to be effective in clearing superficial and nodular BCCs, it is unlikely to alter our current treatment of BCC.
AB - BACKGROUND. Basal cell carcinoma (BCC) is the most common skin cancer. Recently, there has been renewed interest in various immunotherapies in the treatment of BCC. The current study is a randomized, open-label, placebo-controlled trial of intralesional Candida antigen in the treatment of nodular BCC. OBJECTIVE. The objective of this study was to evaluate the safety and efficacy of intralesional Candida antigen in the treatment of BCC. RESULTS. In the control group, no patients had complete clearing of their tumor. In the Candida group, 10 of 17 (56%) patients had complete clearing of their tumor. The Fisher exact test was used to compare the two treatment groups. This showed the difference in clearance rates to be of borderline significance, with a p value of .105. CONCLUSION. Although immunotherapy with repeated injections of Candida antigen appears to be effective in clearing superficial and nodular BCCs, it is unlikely to alter our current treatment of BCC.
UR - http://www.scopus.com/inward/record.url?scp=11844275239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11844275239&partnerID=8YFLogxK
U2 - 10.1097/00042728-200501000-00003
DO - 10.1097/00042728-200501000-00003
M3 - Article
C2 - 15720089
AN - SCOPUS:11844275239
SN - 1076-0512
VL - 31
SP - 16
EP - 18
JO - Dermatologic Surgery
JF - Dermatologic Surgery
IS - 1
ER -